EAM Investors’s Ovid Therapeutics OVID Stock Holding History

EAM Investors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$600K	Buy	+270,298	New	+$483K	0.07%	253
2020 Q4	–	Sell	-121,116	Closed	-$695K	–	364
2020 Q3	$695K	Sell	121,116 -63,612	-34%	-$426K	0.16%	248
2020 Q2	$1.36M	Hold	184,728	–	–	0.3%	162
2020 Q1	$550K	Sell	184,728 -100,337	-35%	-$338K	0.17%	193
2019 Q4	$1.18M	Buy	285,065 +78,947	+38%	+$249K	0.26%	179
2019 Q3	$668K	Buy	+206,118	New	+$468K	0.18%	211

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EAM Investors's OVID Position: Q1 2026 in Review

EAM Investors opened a new position in Ovid Therapeutics (OVID) in Q1 2026: 270,298 shares worth $600K. The stake represents 0.07% of the portfolio and ranks #253 among its holdings. This is a return to the name: EAM Investors previously reported a position in OVID as recently as Q3 2020.

EAM Investors first reported a position in OVID in Q3 2019 and has held it in 6 quarters since. The position peaked at $1.36M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

EAM Investors held 270,298 shares of Ovid Therapeutics worth $600K as of Q1 2026.
Ovid Therapeutics was a new EAM Investors position in Q1 2026.
Ovid Therapeutics made up 0.07% of EAM Investors's portfolio in Q1 2026, its #253 holding.
EAM Investors first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 6 quarters since.
EAM Investors's Ovid Therapeutics position peaked at $1.36M in Q2 2020.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.